{"drugs":["Metolazone","Mykrox","Zaroxolyn"],"mono":{"0":{"id":"373240-s-0","title":"Generic Names","mono":"Metolazone"},"1":{"id":"373240-s-1","title":"Dosing and Indications","sub":[{"id":"373240-s-1-4","title":"Adult Dosing","mono":"<ul><li><b>Congestive heart failure - Edema:<\/b> Zaroxolyn(R), initial, 5 to 20 mg ORALLY once daily<\/li><li><b>Edema - Kidney disease:<\/b> Zaroxolyn(R), initial, 5 to 20 mg ORALLY once daily<\/li><li><b>Hypertension:<\/b> Zaroxolyn(R), initial, 2.5 to 5 mg ORALLY once daily<\/li><li><b>Hypertension:<\/b> Zaroxolyn(R), maintenance, 5 to 20 mg ORALLY once daily<\/li><li><b>Hypertension:<\/b> Mykrox(R), initial, 0.5 mg ORALLY once daily<\/li><li><b>Hypertension:<\/b> Mykrox(R), titrate to maintenance, may increase to 1 mg ORALLY once daily<\/li><li><b>Hypertension:<\/b> Zaroxolyn(R), titration, allow 1 to 6 wk to achieve optimum antihypertensive effect<\/li><\/ul>"},{"id":"373240-s-1-5","title":"Pediatric Dosing","mono":"Safety and effectiveness not established in children"},{"id":"373240-s-1-6","title":"Dose Adjustments","mono":"<b>hemodialysis:<\/b> no dosage supplementation is required following hemodialysis"},{"id":"373240-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><ul><li>Congestive heart failure - Edema<\/li><li>Edema - Kidney disease<\/li><li>Hypertension<\/li><\/ul><b>Non-FDA Labeled Indications<\/b><ul><li>Calcium renal calculus<\/li><li>Edema, due to liver disease<\/li><li>Premenstrual syndrome<\/li><li>Renal failure<\/li><\/ul>"}]},"3":{"id":"373240-s-3","title":"Contraindications\/Warnings","sub":[{"id":"373240-s-3-9","title":"Contraindications","mono":"<ul><li>anuria<\/li><li>hepatic coma or precoma<\/li><li>known allergy or hypersensitivity to metolazone<\/li><\/ul>"},{"id":"373240-s-3-10","title":"Precautions","mono":"<ul><li>arrhythmia, ventricular, history of; increased risk of hypokalemia and dangerous or fatal arrhythmias<\/li><li>azotemia may occur; discontinuation may be necessary<\/li><li>concomitant use with lithium not recommended<\/li><li>cross-allergy may occur in patients allergic to sulfonamide-type drugs, thiazides, or quinethazone<\/li><li>digitalized patients; increased risk of hypokalemia and dangerous or fatal arrhythmias<\/li><li>electrolyte imbalance (eg, hypokalemia, hyponatremia, hypochloremic alkalosis, hypomagnesemia, hypercalcemia) may occur; monitoring recommended<\/li><li>hyperglycemia or manifestation of latent diabetes may occur<\/li><li>hyperuricemia or gout may occur<\/li><li>hypokalemia, dose-related, may occur; increased risk with larger doses, inadequate oral intake, excess extrarenal potassium loss, severe liver disease, or rapid diuresis; monitoring recommended; medical management may be necessary<\/li><li>hypotension, orthostatic, may occur<\/li><li>renal impairment, severe; risk of drug accumulation; discontinuation may be necessary<\/li><li>sensitivity reactions (eg, angioedema, bronchospasm) may occur with or without a history of allergy or asthma<\/li><li>systemic lupus erythematosus; activation or exacerbation has been reported<\/li><\/ul>"},{"id":"373240-s-3-11","title":"Pregnancy Category","mono":"<ul><li>B (FDA)<\/li><li>C (AUS)<\/li><\/ul>"},{"id":"373240-s-3-12","title":"Breast Feeding","mono":"Micromedex: Infant risk cannot be ruled out.<br\/>"}]},"4":{"id":"373240-s-4","title":"Drug Interactions","sub":{"1":{"id":"373240-s-4-14","title":"Major","mono":"<ul><li>Acetyldigoxin (established)<\/li><li>Arsenic Trioxide (theoretical)<\/li><li>Bepridil (theoretical)<\/li><li>Bumetanide (probable)<\/li><li>Deslanoside (established)<\/li><li>Digitalis (established)<\/li><li>Digitoxin (established)<\/li><li>Digoxin (established)<\/li><li>Dofetilide (probable)<\/li><li>Droperidol (theoretical)<\/li><li>Ethacrynic Acid (probable)<\/li><li>Flecainide (theoretical)<\/li><li>Furosemide (probable)<\/li><li>Ketanserin (theoretical)<\/li><li>Levomethadyl (theoretical)<\/li><li>Lithium (probable)<\/li><li>Metildigoxin (established)<\/li><li>Sotalol (probable)<\/li><li>Torsemide (probable)<\/li><\/ul>"},"2":{"id":"373240-s-4-15","title":"Moderate","mono":"<ul><li>Aceclofenac (probable)<\/li><li>Acemetacin (probable)<\/li><li>Alacepril (probable)<\/li><li>Amtolmetin Guacil (probable)<\/li><li>Aspirin (probable)<\/li><li>Benazepril (probable)<\/li><li>Bromfenac (probable)<\/li><li>Bufexamac (probable)<\/li><li>Captopril (probable)<\/li><li>Celecoxib (probable)<\/li><li>Choline Salicylate (probable)<\/li><li>Cilazapril (probable)<\/li><li>Clonixin (probable)<\/li><li>Delapril (probable)<\/li><li>Dexibuprofen (probable)<\/li><li>Dexketoprofen (probable)<\/li><li>Diclofenac (probable)<\/li><li>Diflunisal (probable)<\/li><li>Dipyrone (probable)<\/li><li>Enalapril (probable)<\/li><li>Enalaprilat (probable)<\/li><li>Etodolac (probable)<\/li><li>Etofenamate (probable)<\/li><li>Etoricoxib (probable)<\/li><li>Felbinac (probable)<\/li><li>Fenoprofen (probable)<\/li><li>Fepradinol (probable)<\/li><li>Feprazone (probable)<\/li><li>Floctafenine (probable)<\/li><li>Flufenamic Acid (probable)<\/li><li>Flurbiprofen (probable)<\/li><li>Fosinopril (probable)<\/li><li>Gossypol (probable)<\/li><li>Ibuprofen (probable)<\/li><li>Ibuprofen Lysine (probable)<\/li><li>Imidapril (probable)<\/li><li>Indomethacin (probable)<\/li><li>Ketoprofen (probable)<\/li><li>Ketorolac (probable)<\/li><li>Licorice (probable)<\/li><li>Lisinopril (probable)<\/li><li>Lornoxicam (probable)<\/li><li>Loxoprofen (probable)<\/li><li>Lumiracoxib (probable)<\/li><li>Meclofenamate (probable)<\/li><li>Mefenamic Acid (probable)<\/li><li>Meloxicam (probable)<\/li><li>Moexipril (probable)<\/li><li>Morniflumate (probable)<\/li><li>Nabumetone (probable)<\/li><li>Naproxen (probable)<\/li><li>Nepafenac (probable)<\/li><li>Niflumic Acid (probable)<\/li><li>Nimesulide (probable)<\/li><li>Oxaprozin (probable)<\/li><li>Oxyphenbutazone (probable)<\/li><li>Parecoxib (probable)<\/li><li>Pentopril (probable)<\/li><li>Perindopril (probable)<\/li><li>Phenylbutazone (probable)<\/li><li>Piketoprofen (probable)<\/li><li>Piroxicam (probable)<\/li><li>Proglumetacin (probable)<\/li><li>Propionic Acid (probable)<\/li><li>Propyphenazone (probable)<\/li><li>Proquazone (probable)<\/li><li>Quinapril (probable)<\/li><li>Ramipril (probable)<\/li><li>Rofecoxib (probable)<\/li><li>Salicylic Acid (probable)<\/li><li>Salsalate (probable)<\/li><li>Sodium Salicylate (probable)<\/li><li>Spirapril (probable)<\/li><li>Sulindac (probable)<\/li><li>Temocapril (probable)<\/li><li>Tenoxicam (probable)<\/li><li>Tiaprofenic Acid (probable)<\/li><li>Tolfenamic Acid (probable)<\/li><li>Tolmetin (probable)<\/li><li>Trandolapril (probable)<\/li><li>Valdecoxib (probable)<\/li><li>Zofenopril (probable)<\/li><\/ul>"}}},"5":{"id":"373240-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Cardiovascular:<\/b>Orthostatic hypotension<\/li><li><b>Endocrine metabolic:<\/b>Electrolytes abnormal, Hyperuricemia<\/li><li><b>Neurologic:<\/b>Dizziness<\/li><li><b>Other:<\/b>Fatigue<\/li><\/ul><b>Serious<\/b><ul><li><b>Dermatologic:<\/b>Necrotizing vasculitis, Stevens-Johnson syndrome, Toxic epidermal necrolysis<\/li><li><b>Gastrointestinal:<\/b>Pancreatitis<\/li><li><b>Hematologic:<\/b>Agranulocytosis, Hypoplastic anemia, Venous thrombosis<\/li><li><b>Hepatic:<\/b>Cholestatic jaundice syndrome, Hepatitis<\/li><li><b>Neurologic:<\/b>Seizure<\/li><\/ul>"},"6":{"id":"373240-s-6","title":"Drug Name Info","sub":{"0":{"id":"373240-s-6-17","title":"US Trade Names","mono":"<ul><li>Mykrox<\/li><li>Zaroxolyn<\/li><\/ul>"},"2":{"id":"373240-s-6-19","title":"Class","mono":"<ul><li>Cardiovascular Agent<\/li><li>Diuretic<\/li><li>Thiazide Related<\/li><\/ul>"},"3":{"id":"373240-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"373240-s-6-21","title":"Generic Availability","mono":"Yes<br\/>"}}},"7":{"id":"373240-s-7","title":"Mechanism Of Action","mono":"Metolazone is a diuretic, saluretic, and antihypertensive drug of the quinazoline class with characteristics generally comparable with thiazide diuretics. Its actions result from interfering with electrolyte reabsorption in the renal tubules. Metolazone primarily inhibits sodium reabsorption at the distal convoluted tubule, and to a lesser extent, in the proximal convoluted tubule.<br\/>"},"8":{"id":"373240-s-8","title":"Pharmacokinetics","sub":{"0":{"id":"373240-s-8-23","title":"Absorption","mono":"<ul><li>Tmax, Oral: 8 hours<\/li><li>Bioavailability, Oral: 40% to 65%<\/li><\/ul>"},"2":{"id":"373240-s-8-25","title":"Metabolism","mono":"Site unspecified: small fraction <br\/>"},"3":{"id":"373240-s-8-26","title":"Excretion","mono":"<ul><li>Renal excretion: 56.1% (oral); 87.5% (IV)  (unchanged)<\/li><li>Renal excretion, renal transplant patients: reduced<\/li><li>Dialyzable: No (hemo)<\/li><\/ul>"},"4":{"id":"373240-s-8-27","title":"Elimination Half Life","mono":"8 to 14 hours <br\/>"}}},"10":{"id":"373240-s-10","title":"Monitoring","mono":"<ul><li>blood pressure, urine output, reduction in edema<\/li><li>serum and urine electrolytes (eg; potassium, sodium, magnesium, calcium)<\/li><li>renal function, hepatic function<\/li><\/ul>"},"11":{"id":"373240-s-11","title":"How Supplied","mono":"<ul><li><b>Generic<\/b><br\/>Oral Tablet: 2.5 MG, 5 MG, 10 MG<br\/><\/li><li><b>Zaroxolyn<\/b><br\/>Oral Tablet: 2.5 MG, 5 MG<br\/><\/li><\/ul>"},"12":{"id":"373240-s-12","title":"Toxicology","sub":[{"id":"373240-s-12-31","title":"Clinical Effects","mono":"<b>DIURETICS<\/b><br\/>USES: Class of drugs that are primarily used to treat hypertension and congestive heart failure. Potassium sparing diuretics and carbonic anhydrase inhibitors are covered in separate managements. PHARMACOLOGY: Work in a variety of mechanisms including inhibiting sodium and chloride reabsorption in the distal convoluted tubule (thiazides), inhibiting transport of sodium, potassium, and chloride in the thick ascending limb of the loop of henle (loop), and osmotic agents (mannitol). TOXICOLOGY: Produce hypovolemia and electrolyte deficiencies. EPIDEMIOLOGY: Rare overdose which uncommonly results in significant morbidity or death. MILD TO MODERATE TOXICITY: Mild dehydration, tachycardia, dry mucous membranes, headache, muscle cramps, thirst, and brisk diuresis. Large doses of furosemide or ethacrynic acid can cause ototoxicity. SEVERE TOXICITY: Hypotension, hypochloremic metabolic alkalosis, mental status changes, and electrolyte abnormalities (i.e. hypokalemia, hypomagnesemia, hypochloremia, hypocalcemia) are the most common manifestations of severe poisoning. Rarely muscle spasms, tetany, seizures, coma, or dysrhythmias may develop secondary to severe electrolyte abnormalities.  CNS depression has been reported rarely in children with acute ingestion without significant electrolyte abnormalities. ADVERSE EFFECTS: Thiazides are associated with hyperglycemia and hyperlipidemia. Furosemide has been associated with ototoxicity, hyperglycemia, and hypercholesterolemia.  Diuretics have a large number of drug interactions as well. Extravasation of mannitol can cause tissue injury and compartment syndrome.<br\/>"},{"id":"373240-s-12-32","title":"Treatment","mono":"<b>DIURETICS<\/b><br\/><ul><li>Support: MANAGEMENT OF MILD TO MODERATE TOXICITY: Patients with minor symptoms can be managed with supportive care only.  Oral hydration and oral electrolyte supplementation may be sufficient.  Severe electrolyte disturbances and\/or mental status changes indicate a more severe poisoning. MANAGEMENT OF SEVERE TOXICITY: Severe toxicity is very rare. Treatment should be directed at intravenous correction of volume loss and electrolyte abnormalities.<\/li><li>Decontamination: PREHOSPITAL: Prehospital decontamination is not indicated as toxicity is rare. HOSPITAL: Activated charcoal is rarely  indicated as acute toxicity is rare.<\/li><li>Airway management: Diuretic poisoning should not produce symptoms mandating airway management.<\/li><li>Antidote: There is no specific antidote.<\/li><li>Monitoring of patient: Monitor vital signs and serum electrolytes.  Obtain an ECG in patients with significant electrolyte abnormalities.<\/li><li>Enhanced elimination procedure: Hemodialysis is not expected to be helpful.<\/li><li>Patient disposition: HOME CRITERIA: Asymptomatic patients with inadvertent ingestion of less than a maximal daily dose can be monitored at home. OBSERVATION CRITERIA: Adults with intentional ingestions or symptomatic children should be referred to a health care facility.  Patients who are asymptomatic after 6 hours can be discharged home. ADMISSION CRITERIA: Patients who have severe electrolyte abnormalities or vital sign abnormalities should be admitted. CONSULT CRITERIA: Consult a poison center or medical toxicologist for assistance in managing severe poisonings.<\/li><\/ul>"},{"id":"373240-s-12-33","title":"Range of Toxicity","mono":"<b>DIURETICS<\/b><br\/>TOXICITY: Toxic doses are not well established.  Diuresis is expected to result at even therapeutic doses.  Toxicity is most common with chronic dosing and acute toxicity is often related to other factors such as comorbid conditions and access to fluid replacement. THERAPEUTIC DOSE: Furosemide is typically dosed at 20 to 80 mg with repeat doses as necessary in adults; pediatric dose is 1 to 2 mg\/kg orally.  Hydrochlorothiazide is typically dosed at 12.5 to 50 mg daily in adults; pediatric dose is 1 to 3 mg\/kg divided twice daily.<br\/>"}]},"13":{"id":"373240-s-13","title":"Clinical Teaching","mono":"<ul><li>Patient should avoid activities requiring coordination until drug effects are realized, as drug may cause dizziness.<\/li><li>This drug may cause syncope, hyperuricemia, headache, depression, nocturia, or impotence.<\/li><li>Instruct patient to report signs\/symptoms of hypotension, chest pains, or palpitations.<\/li><li>Advise patient to report nocturia, as dose timing may need adjustment to allow for uninterrupted sleep.<\/li><li>Warn patient against sudden discontinuation of drug, as rebound hypertension may occur.<\/li><li>Tell patient to not drink alcohol while taking this drug.<\/li><li>Patient should avoid concomitant lithium during therapy.<\/li><\/ul>"}}}